NCT04555096View on ClinicalTrials.gov

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions
Covid19SARS-CoV-2 Infection
Interventions
DRUG

GC4419

180 Minute IV Infusion

DRUG

Placebo

180 Minute IV Infusion

Trial Locations (3)

52242

University of Iowa, Iowa City

63110

Saint Louis University, St Louis

63141

Mercy Research, St Louis

Sponsors
All Listed Sponsors
lead

Galera Therapeutics, Inc.

INDUSTRY

NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 | Biotech Hunter | Biotech Hunter